Table 1. Baseline characteristics of the study cohort (n=99).
| Variable | n (% missing) | Median [IQR] or count (%) |
|---|---|---|
| Demographics | ||
| Age (years) | 99 (0%) | 61 [55-67] |
| Female Gender | 99 (0%) | 37 (37.4%) |
| BMI (kg/m2) | 99 (0%) | 24.3 [21.7-27.9] |
| History of smoking | 93 (6.1%) | 37 (39.8%) |
| History of TEE* | 99 (0%) | 4 (4.0%) |
| Tumour specifics | ||
| Location of primum within colorectum | / | / |
| ---Rectum | / | 36 (40.4%) |
| ---Sigmoid colon | / | 24 (27.0%) |
| ---Right sided primary | / | 23 (25.8%) |
| ---Others / not specified | / | 16 (16.2%) |
| Synchronous metastasis | 99 (0%) | 58 (58.6%) |
| Number of metastatic sites | 99 (0%) | 1 [1-2] |
| ---Liver | / | 80 (80.8%) |
| ---Lungs | / | 35 (35.4%) |
| Therapeutic management | ||
| Palliative intent | / | 89 (89.9%) |
| Neoadjuvant intent | / | 10 (10.1%) |
| CTX prior to inclusion* | / | 3 (3.0%) |
| Surgical resection of tumour | 80 (19.2%) | 70 (87.5%) |
| Secondary metastasectomy | 99 (0%) | 28 (28.3%) |
| 1st line CTX data | 98 (1.0%) | / |
| ---FU-oxaliplatin combinations | / | 62 (63.3%) |
| ---FU-irinotecan combination | / | 17 (17.3%) |
| ---FU-monotherapy | / | 8 (8.2%) |
| ---Oxaliplatin-raltitrexed combination | / | 6 (6.1%) |
| ---Bevacizumab | / | 57 (58.2%) |
| ---anti-EGFR-therapy | / | 9 (9.2%) |
| Number of chemotherapy cycles | 94 (5.1%) | 6 [3-6] |
| 2nd line CTX | 99 (0%) | 52 (52.5%) |
| Pretherapeutic haemostatic biomarkers | ||
| Factor VIII (% activity) | 98 (1.0%) | 219 [158-262] |
| sP-Selectin (ng/mL) | 99 (0%) | 41.2 [31.6-53.1] |
| D-dimer (μg/mL) | 93 (6.1%) | 1.05 [0.51-2.24] |
| Prothrombin Fragment 1.2 (pmol/L) | 94 (5.1%) | 265 [217-379] |
| Peak thrombin generation (nmol/L) | 99 (0%) | 430.3 [300.3-573.2] |
| Fibrinogen (mg/dl) | 99 (0%) | 463 [382-555] |
Column 1: Variable name or subsection headline; Column 2: n: number of patients with data present on specific variable; % missing: percentage of missing data in the total study population (99 patients); Column 3: Distribution of continuous variables (median, IQR); absolute and relative frequency of nominal variables;
*
according to CATS, prior VTE and termination of prior chemotherapy had to be ≥3 months before enrolment;
Abbreviations: IQR: interquartile-range; BMI: body mass index; TEE: thromboembolic events; CTX: chemotherapy; FU: fluoropyrimidine; EGFR: epidermal growth factor receptor;